ANDA 62677, held by Sun Pharm Industries. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 62677 (Doxycycline Hyclate), held by Sun Pharm Industries, was first approved by FDA on Jul 10, 1986, with 29 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 10, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Apr 1, 2025 | Supplement 59Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 53Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 51Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 50Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 49Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 47Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 46Labeling · Standard review | Approved | None posted |
| Dec 23, 2015 | Supplement 43Manufacturing | Approved | None posted |
| Sep 10, 2015 | Supplement 41Labeling · Standard review | Approved | None posted |
| Jul 24, 2013 | Supplement 39Labeling · Standard review | Approved | None posted |
| Nov 30, 2011 | Supplement 34Labeling | Approved | None posted |
| May 29, 2008 | Supplement 30Labeling | Approved | None posted |
| Sep 28, 2006 | Supplement 28Labeling | Approved | None posted |
| Mar 8, 2006 | Supplement 24Labeling | Approved | None posted |
| Jul 6, 2005 | Supplement 20Labeling | Approved | None posted |
| Apr 1, 2003 | Supplement 17Labeling | Approved | None posted |
| Feb 26, 2002 | Supplement 14Labeling | Approved | None posted |
| Apr 12, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Dec 28, 2000 | Supplement 12Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 11Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 10Manufacturing | Approved | None posted |
| Dec 5, 1997 | Supplement 9Manufacturing | Approved | None posted |
| Feb 24, 1997 | Supplement 8Manufacturing | Approved | None posted |
| Jun 22, 1995 | Supplement 7Manufacturing | Approved | None posted |
| Jan 12, 1994 | Supplement 6Manufacturing | Approved | None posted |
| Jul 6, 1993 | Supplement 5Labeling | Approved | None posted |
| Mar 26, 1993 | Supplement 4Labeling | Approved | None posted |
| Mar 16, 1992 | Supplement 3Labeling | Approved | None posted |
| May 1, 1989 | Supplement 1Manufacturing | Approved | None posted |
| Jul 10, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters